µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ "dG N0i
ll1N`ke
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ Dn@ZS _f
x`FTy&g
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ M 87CP=yc
\q*-9_M
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© X(eW
+,H
fI`gF^u(
1. CD4 [|YvVA
b9#(I~}
2. T cell receptor(TCR) *l4[`7|
~c<8;,cjYR
3. immunoglobulin superfamily (IgSF) dt@c,McN|Q
+or
<(%o @
4. selectin UimofFmI%
{J
izCUo_'
5. anti-idiotypic antibody (¦ÁId) Axns
8#lq:
6. major histocompatibility complex(MHC) WA,D=)GP
vG'#5%,|
7. immunotolerance KpYezdPF)
`_ 1~[t
8. biological reponse modifier(BRM) h'};spv
ZIa,pON
9. immune reponse gene (Ir gene) 6 5dMv*{
{pH# zs4Y
10. reshaped antibody (or reconstituted antibody) _"B.V(
,3 /o7 '
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© c't
QA
G\BZ^SwE
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ iLZY6?_^
~?Ky{jah:^
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? _3@5@1[s
O7
aLW
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ i(;`x
p>+9pxx~U
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? cbyzZ#WRb
[Cv./hEQi
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) \alV #>J5
)h]#:,pm
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ Zf@B<
m
}|=/v(D
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? x+Xd7N1
2L 1,;
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? Q l)hIf$Oo
hk4t #Km
¡¡ gx9
Os2Z|3
;C$+8%P4
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ D;V[9E=g/
ZK^cG'^2|
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? PmE)FthdP(
950N\Y@u
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? #mu L-V
h7"U1'b
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 7amVnR1f
>Dr(%z6CN
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ JyM
k @Y
+`Z1L\gmA
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ gfg,V.:
E:pk'G0bZ
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© J/4T =:\
RtM
I[
1. CD8 29RP$$gR
?8V.iHJk
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) MJ)lZ!KZ
j1K3|E
3. immunoglobulin fold(Ig fold) l:V
R8g[
h$l/wn
4. cadherin (Ca-dependent cell adhesion moleculers) ]u_j6y!
XA2Ld
5. idiotype-anti-idiotypic antibody immune network theory /e '3\,2_
Wm}c-GD
6. HLA class II antigen -XV,r<''
P9cx&Hk9
7. complementarity-determining region (CDR) X,|8Wpi=
&n k)F<
8. perforin(or pore-forming protein ,PFP) QO'Hyf t
v03cQw\"WE
9. high affinity IL-2 receptor M5`v^>
C Bkoky9&
10. artificial active immunization ;l@94
)@0
Yr9'2.%Q
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© b{A[\ "
buGBqx[
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠXsq
@E#@S
4mX(.6
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 }
!m43x/&
q#K{~:
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ }Ce9R2
8MJJ w;
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ @j46Ig4~b
&`D$w?beg
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) !vSI"$xd
Ds`e-X)O;\
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ MpCPY"WLL
D#g-mqar:
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? -+".ut:R
Q
dj(D\.
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 0j$\k|xFXZ
;2f=
d_/x
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ^)AECn
?J
rUZXY
¡¡ 42Z:J 0
iM]O
/JD}
b[J$
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ m}]{Y'i]R
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ NQdwj>_a
o0H^J,6gV
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ $S6(V}yh
GkAd"<B
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© {
*_Ln
vt
EfH
1. immunoglobulin gene rearrangement '@n"'vks(\
{wSi?;[Gq
2. the common chain of cytokine receptor (or a cytokine receptor _J,**AZ~z
$fb%?n{
subunit shared by some cytokine receptors) lu#a.41
+t7HlAXB#
3. flow cytometry(FCM) HhbBt'fH
{v"f
){
4. carrier effect l6'KIg
}e7Rpgu
5. positive selection of T lymphocytes in thymus 7[Us.V@
*l7 `C)
6. mouse TH1(Th1) and TH2(Th2) subsets ~kc#"^sJ
`_J&*Kk5
7. perforin (pore-forming protein ,PFP)
0:{W
t
wSR|uh
8. ADCC(antibody-dependent cell-mediated cytotoxicity) Ar%*NxX
MWwqon|
9. SH-2(src-homology region 2) G4
7^xR
HNkOPz+d&8
10. Ab2¦Â (internal image) }s2CND
;D'm=uOl
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 9/"&6,
eC/{c1C
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? /KH85/s
C:1(<1K
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? AO<T6VK
$HwF:L)*
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ+}jzge"
;(K/O?nrJ
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ k4#j
l<R
g9C-!X-<T
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠV@0T&#
.H|Z3d!Jj
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) %LnLB
.BxI~d^
ÃâÒßѧרҵ£º 9@1n:X
Ry[7PLn]
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ Qi\]='C
x)80:A}
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? ;)ay uS sQ
/yU#UZ4;
´«È¾²¡Ñ§×¨Òµ£º cRI2$|
a@g
<cl7a,
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ q?frt3o
W.
d',4)
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ pI f6RwH}%
548L^"D
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ 9@qkj
4w
R?{_Q<17
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? <uU<qO;6
7j|CWur
vq
v$\<L|
^vm6JWwN0B
\e'Vsy>q
+Zi+
/9Z(H
0fj C>AS
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ t=eI*M+>h
I>rTqOK
ÃâÒßѧÊÔÌâ RKzO$T
{zd[8TJ~xa
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© P,zQl;
4'3;{k$z
1. Fas(CD95)/FasL ^$dbyj`
#Fo#f<bp
2. common chain of cytokine receptor ]Ndy12,M
|[r7B*fw
3 . TCR/CD3 complex RU#}!Kq
G8'{nPA~
4. negaive selection of thymocytes g/l:q&Q<
wIAH,3
!
5. artificial active immune N,B!D~@
QiA}0q3]0
6. anti-idiotypic #Rfcp!
"N'W~XPG
7. IgSF T_s09Wl
dYOY8r/
8. Integrin 2oc18#iG(
L1+s0g>
9. chemokine
{d#sZT
P9:5kiP H
10. B7/CD28 t@R n#(~"
&=S:I!9;;
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© og8hc~:ro
:B=Gb8?
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ }M(xN6E
WqM| nX
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ K:XP;#OsP
|RD)pvVM
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ 9D
`K#3}
]zAwKuIK
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ Odw'Ua
0=U|7%dOL
%A3m%&(m&%
{U>N*&_`
R|$b\3
i?b9
zn
9MO=f^f-
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ [aA@V0l
L58#ri=
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 'wYIJK~1
rp"5176
1. B7/CD28 A15Kj#Oy
1,h:|
2. Th1 subset M?My+o T
cNwHY
Z'
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© mj9sX^$dE
gjz-CY.hz
4. antibody affinity maturation %x{kd8>u!
/W*Z.
5. AP-1 %GY'pQz
}
)Lz%Z
6. single chain variable fragment£¨ScFv£© w1-P6cf
Cy/VH"G=
7. NK cell receptor U+>M@!=
.QKyB>s
8. Zinkernagel-Doherty phenomenon T^`; wD
JrY*K|YdW
9. Ig fold x$o^;2Z
6YNL4HE?
10. CD40/CD40L =z"+)N
i@5Fne
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© 4P1}XYD-2
dTK0lgkUE
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 8Vj'&UY
6*>L
ud
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ jMTM:~0N
LOi}\O8
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ ,I5SAd|dX
s^eiym P
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ }kr?+)wB
&5R|{',(Y
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ ML\>TDt
:p:
C
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ ]r|oNGD)G
n8F5z|/
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ R'tK
J_VI
edq,:
LO{Axf%
Wvr{
l
?![[la+f
.M^[/!
!>`Fg>uy
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ R03 Te gwA
<ErX<(0`ig
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© *$<W"@%^J
a9.y
uSzL
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© m|qktLx
r!2U#rz
1.Co-stimulators (or co-stimulating molecules) T[bC Y 6
?@.v*'qR
2.NK-kB aZWj52
pZ.b
X
3.Immunoglobulin superfamily HYfGu1j?X
tR|dnC4U
4.antigen-presenting cell (APC)
-BSdrP|
Ur(R[*2bx
5.death domain \#_ymM0
QJVbt
6.CCR and CXCR -r={P_E6
GXtK3
YAr
7.Lectin (or mitogen) [k6I#v<&
G.rz6o;
8.Clusters of differentiation, CD) lvO6&sF1
K*>%,mP$i
9.B7 family q!ZM Wg
!ZYPz}&N_
10.Cytotoxic T lymphocyte, CTL) 8W\yM;'
m2j&0z
11.IL-15 and IL-15 receptor (IL-15R) K92j BR
KewW8H~tb
12.MHC restriction 8 "l
PiW3
.AfZ5s]/F
13.Affinity-chromatography 9TW[;P2> )
3p0v
14.Cyctosprin A, CsA QyD0WC}i
K-0=#6?y4
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) q/#e6;x
@Rr=uf G
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© M@Th^yF+8H
5\+*ml
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 EoAr}fI
PG&t~4QM`
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ IO\l8G
e\%,\uV}
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ fN&,.UB^p
'ygKP6M
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© a-{|/
n%
,mHME~
ÃâÒßѧרҵ£º TSB2]uH
+:
S`]
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ '+88UFSq5
B=|R?t (*
Ïû»¯ÄÚ¿Æ£º i2=- su
:zY4phR
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ )bUnk+_
y]db]pP5
ѪҺ²¡Ñ§×¨Òµ£º l_g$6\&|
M\]lNQ A
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ PLCm\Oh$l
? i{?Q,
.5|[gBK
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ thjr1y.e
6}"%>9
(רҵ»ù´¡: ÃâÒßѧ) qG9a!sj
}z`x-(V
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) IiPX`V>RC
m
Q2i$ 0u
1. ADCC(antibody dependent cell-mediated cytotoxicity) _2fW/U54_
OSBR2Z;=
2. »·æß¾úËØ(cyclosporin) \s=r[0tj!
zL"e .
3. KIR(killer cell inhibitory receptor) 'O<b'}-A
{ DYY9MG8
4. HLDA(human leucocyte differentiation antigen) kWr1>})'
q5f QTV
5. Interleukin 18(IL-18) `OW'AS |
"Bd-h|J
6. ÕûºÏËØ(integrin) /YJo"\7
;Q{D]4
7. Fas/FasL +X
WTu!
|"*P`C=
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
2E*=EjGV
rJiF2 W
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) x6cG'3&T
e$9a9twl
10. Th1/Th2 PzJ(Q
[UwQi!^-O
11. »ùÒòÒßÃç(DNAÒßÃç) /\1'.GR
)Jt.
Z^J<
12. chemokines and chemokine receptor B-
@bU@H
@`[e1KQ
13. ÃâÒßÄÍÊÜ v!I z&M:z
Y -it3q'Z
14. ¹²´Ì¼¤·Ö×Ó sc*R
:"
%pVsafV
15. ËÀÍö½á¹¹Óò(death domain) "](Q2
lf"w/pb'
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) EV6R[2kl
vHvz-3
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? lw3H
8[
;!f='QuA
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠgdIk%m4
+2MF#{ tS
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 2S7BzZ/
3$"V,_TBZ
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ 8Yc-3ozH
syu/"KY^!
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå (?Ko:0+*
h] ho? K
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ lL zR5445)
{N]WVp*R
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£